QS Investors’s NovoCure NVCR Stock Holding History

QS Investors’s Portfolio NVCR Stock Details NVCR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	$358K	Hold	1,612	–	–	﹤0.01%	871
2021 Q1	$214K	Sell	1,612 -6,850	-81%	-$1.08M	﹤0.01%	1106
2020 Q4	$1.46M	Buy	8,462 +212	+3%	+$29K	0.02%	404
2020 Q3	$919K	Sell	8,250 -47,910	-85%	-$3.83M	0.01%	465
2020 Q2	$3.33M	Sell	56,160 -110	-0.2%	-$7.23K	0.05%	316
2020 Q1	$3.79M	Buy	56,270 +260	+0.5%	+$20.5K	0.06%	255
2019 Q4	$4.3M	Sell	56,010 -590	-1%	-$47.6K	0.04%	321
2019 Q3	$4.23M	Buy	56,600 +11,500	+25%	+$920K	0.05%	314
2019 Q2	$2.85M	Hold	45,100	–	–	0.03%	461
2019 Q1	$2.17M	Buy	45,100 +43,000	+2,048%	+$2.07M	0.02%	569
2018 Q4	$70K	Buy	+2,100	New	+$76.8K	﹤0.01%	1404

Other funds holding NVCR

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

QS Investors's NVCR Position: Q2 2021 in Review

QS Investors held its NovoCure (NVCR) position steady in Q2 2021 at 1,612 shares worth $358K. The position accounts for ﹤0.01% of the portfolio, ranked #871.

QS Investors first reported a position in NVCR in Q4 2018 and has held it in 11 quarters since. The position peaked at $4.3M in Q4 2019. 362 funds tracked by Wall St. Rank hold NVCR as of Q2 2021.

QS Investors held 1,612 shares of NovoCure worth $358K as of Q2 2021.
QS Investors left its NovoCure share count unchanged in Q2 2021.
NovoCure made up ﹤0.01% of QS Investors's portfolio in Q2 2021, its #871 holding.
QS Investors first reported a position in NovoCure in Q4 2018 and has held it in 11 quarters since.
QS Investors's NovoCure position peaked at $4.3M in Q4 2019.
362 funds tracked by Wall St. Rank held NovoCure as of Q2 2021.

Based on QS Investors's 13F filing for Q2 2021, filed 13 Aug 2021.